- Home
- EVRG vs RPRX Comparison
EVRG vs RPRX Comparison
Compare EVRG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVRG
- RPRX
- Stock Information
- Founded
- EVRG 2017
- RPRX 1996
- Country
- EVRG United States
- RPRX United States
- Employees
- EVRG N/A
- RPRX N/A
- Industry
- EVRG Power Generation
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- EVRG Utilities
- RPRX Health Care
- Exchange
- EVRG Nasdaq
- RPRX Nasdaq
- Market Cap
- EVRG 14.2B
- RPRX 11.7B
- IPO Year
- EVRG N/A
- RPRX 2020
- Fundamental
- Price
- EVRG $60.50
- RPRX $24.47
- Analyst Decision
- EVRG Buy
- RPRX Strong Buy
- Analyst Count
- EVRG 7
- RPRX 6
- Target Price
- EVRG $62.57
- RPRX $41.67
- AVG Volume (30 Days)
- EVRG 1.8M
- RPRX 2.9M
- Earning Date
- EVRG 11-07-2024
- RPRX 02-13-2025
- Dividend Yield
- EVRG 4.37%
- RPRX 3.43%
- EPS Growth
- EVRG 25.01
- RPRX 518.56
- EPS
- EVRG 3.70
- RPRX 2.55
- Revenue
- EVRG $5,777,800,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- EVRG $6.48
- RPRX $12.21
- Revenue Next Year
- EVRG $2.83
- RPRX $11.13
- P/E Ratio
- EVRG $16.51
- RPRX $9.58
- Revenue Growth
- EVRG 3.18
- RPRX N/A
- 52 Week Low
- EVRG $48.04
- RPRX $24.46
- 52 Week High
- EVRG $65.47
- RPRX $31.66
- Technical
- Relative Strength Index (RSI)
- EVRG 29.35
- RPRX 28.15
- Support Level
- EVRG $61.59
- RPRX $24.70
- Resistance Level
- EVRG $62.76
- RPRX $25.28
- Average True Range (ATR)
- EVRG 0.86
- RPRX 0.48
- MACD
- EVRG -0.39
- RPRX -0.12
- Stochastic Oscillator
- EVRG 0.22
- RPRX 0.45
About EVRG Evergy Inc.
Evergy is a regulated electric utility serving eastern Kansas and western Missouri. Major operating subsidiaries include Evergy Metro, Evergy Kansas Central, Evergy Missouri West, and Evergy Transmission Co. The utility has a combined rate base of approximately $20 billion, about half in Kansas and the rest split between Missouri and federal jurisdiction. Evergy is one of the largest wind energy suppliers in the US.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.